Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Blood tests., Biopsy, Imaging tests, Molecular tests), By Product (Instruments, Assay kits & reagents), By End-User (Hospitals, Specialty clinics, Diagnostic Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Blood Cancer Diagnostics Market Size

The global blood cancer diagnostics market size was valued at USD 11.17 billion in 2025 and is projected to grow from USD 11.90 billion in 2026 to USD 19.79 billion by 2034, registering a CAGR of 6.56% during the forecast period from 2026 to 2034. North America dominated the blood cancer diagnostics market with a market share of 38.4% in 2025.

Blood cancer diagnostics encompass a variety of medical tests and procedures used to detect and identify cancers affecting the blood, including leukemia, lymphoma, and myeloma. These cancers typically originate in the bone marrow or lymphatic system, disrupting the normal production of blood cells. Common diagnostic methods include blood tests, such as a CBC, bone marrow biopsies, imaging techniques like CT scans and MRIs, and molecular genetic tests that detect DNA abnormalities in blood cells. Early and accurate detection is essential for effective treatment, as blood cancers often progress rapidly if left untreated.

The global blood cancer diagnostics market is experiencing rapid growth, driven by an increasing number of diagnoses and advancements in diagnostic technologies. The integration of cutting-edge technologies like AI, machine learning, deep learning, next-generation sequencing, and non-invasive sampling is enhancing the accuracy and speed of diagnosis. These innovations are improving early detection and treatment planning, leading to higher survival rates among patients and further propelling market growth.

According to recent data, the three major types of blood cancer leukemia, lymphoma, and myeloma affect the blood, bone marrow, and lymphatic system, with lymphoma accounting for the highest percentage of cases in the U.S. in 2024. Government initiatives, funding, and awareness programs are vital drivers of the market's growth, helping to increase early detection and improve patient outcomes. Moreover, the growing demand for advanced diagnostic tests presents opportunities for major manufacturers to enhance their offerings and strengthen their presence in the blood cancer diagnostics industry.

Test Type Insights

The blood test segment leads the market due to its high accuracy and essential role in early detection. Blood tests, such as multi-cancer early detection (MCED) tests, offer improved sensitivity by combining molecular analysis of liquid biopsies with AI, enabling better differentiation of tumor types. For example, in March 2023, these tests were shown to lower cancer mortality by detecting cancers at earlier stages, highlighting their importance in precision diagnosis and early intervention.

Request Customizationto receive a tailored report.

Product Insights

The instruments segment holds the largest market share in blood cancer diagnostics, driven by the demand for advanced, accurate, and rapid diagnostic results. Instruments like PCR, flow cytometry, and next-generation sequencing (NGS) are essential for detecting biomarkers or genetic changes linked to blood cancers such as leukemia, lymphoma, and myeloma. These technologies enhance early detection, improve diagnosis accuracy, and play a pivotal role in the market's revenue growth.

End-User Insights

Hospitals dominate the blood cancer diagnostic market, holding the largest share due to their provision of advanced diagnostic methods, timely results, and comprehensive care. Hospitals offer services like personalized medicine, state-of-the-art diagnostic tools, and emergency treatment, which are crucial for effective blood cancer diagnosis and management. With their ability to provide immediate and accurate results, hospitals remain central to the market’s growth, offering both diagnostic solutions and post-diagnosis care for patients.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America leads the global blood cancer diagnostics market, driven by access to advanced technologies, robust healthcare infrastructure, and a high prevalence of blood cancer. The region benefits from significant funding and support from both government and private sectors, alongside numerous initiatives and awareness programs.

Moreover, the increasing number of research and development studies, along with technological advancements in diagnostic techniques, is propelling market growth. The region's growing emphasis on cost-effective healthcare solutions further accelerates the expansion of the blood cancer diagnostic market.

The U.S. leads the global market, driven by advanced healthcare infrastructure, significant research investments, and a high prevalence of leukemia, lymphoma, and myeloma. In May 2024, reports estimated that these cancers would account for 9.4% of new cancer cases in the U.S. The demand for early detection and precise diagnostics fuels market growth, with innovations like next-generation sequencing and liquid biopsy enhancing diagnostic accuracy and patient outcomes.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Blood Cancer Diagnostics Market Trends

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is attributed to factors such as the increasing need for infrastructure, technologies, diagnostic tests for cancer treatment, and a large population with growing healthcare needs. Moreover, the region benefits from improving infrastructure, government initiatives promoting cancer awareness, and a growing demand for affordable cancer diagnostic tests and services.

China’s vast population and expanding healthcare infrastructure drive demand for advanced blood cancer diagnostics. Research institutions are developing AI-powered tools for early cancer detection, such as Shanghai Jiao Tong University’s July 2024 innovation, which diagnoses cancer from a single drop of dried blood using nanoparticle-enhanced mass spectrometry. These advancements aim to improve early-stage detection, particularly in rural regions, positioning China as a leader in integrating AI and molecular diagnostics for cancer screening.

India's rapidly growing blood cancer diagnostics industry is driven by rising cancer incidence, expanding healthcare access, and government initiatives. Programs like the DHR-ICMR Advanced Molecular Oncology Diagnostic Services, launched in January 2023, provide advanced molecular diagnostic services across government medical colleges, improving access to early detection. Moreover, increased awareness campaigns and investment in cutting-edge technologies like liquid biopsy and AI-powered genetic testing further strengthen India’s role.

Europe Blood Cancer Diagnostics Market Trends

Germany stands out in Europe's market due to its emphasis on healthcare innovation, widespread use of advanced diagnostic methods like flow cytometry and genetic testing, and strong government-backed research funding. The country’s commitment to precision medicine and early cancer detection accelerates market share. With initiatives promoting AI-driven diagnostics and biomarker-based testing, Germany continues to set benchmarks for cutting-edge cancer research and diagnostic advancements.

France’s strong healthcare system and research-driven approach fuel growth in the market. The country prioritizes innovation, with programs like the November 2024 LEUKEMIA 360 event in Paris, bringing together industry experts, academics, and healthcare professionals to advance leukemia research. This event promotes collaboration and accelerates the development of novel diagnostic solutions, enhancing early detection and personalized treatment strategies for blood cancer patients across the country.

Middle East and Africa Blood Cancer Diagnostics Market Trends

Saudi Arabia’s market benefits from government-backed initiatives and investments in molecular testing and imaging technologies. In January 2024, QIAGEN expanded its presence in the Middle East by opening a regional headquarters in Riyadh, fostering collaboration in precision diagnostics. The country’s focus on advanced healthcare infrastructure, combined with AI-driven diagnostic tools, enhances early detection capabilities and reinforces Saudi Arabia’s position as a key player in the Middle Eastern diagnostics market.

Company Market Share

Key players in the industry are focusing on adopting key business strategies such as strategic collaborations, product approvals, acquisitions, and product launches to gain a strong foothold in the market. Companies are investing in research and development to enhance diagnostic accuracy and efficiency, integrating AI and molecular diagnostics for early cancer detection.

Guardant Health: An Emerging Player in Global Blood Cancer Diagnostics Market

Guardant Health, founded in 2012, is a pioneer precision medicine company dedicated to maintaining wellness and securing more cancer-free years for patients. The company revolutionizes cancer diagnostics by leveraging cutting-edge technologies, including next-generation sequencing (NGS), liquid biopsies, and AI-driven analytics. Guardant Health’s comprehensive testing solutions analyze blood, tissues, and real-world data to detect cancer at its earliest stages, guide treatment decisions, and monitor disease progression.

Recent Developments by Guardant Health:

• In June 2024, Guardant Health launched an updated version of its Guardant360 TissueNext test. This improved Medicare-covered test allows oncologists to have a more streamlined workflow and get results faster, helping them make the most accurate blood cancer diagnostics treatment decisions.

List of Key and Emerging Players in Blood Cancer Diagnostics Market